NCT05122962Recruiting

Pathophysiologic Mechanism for Arrhythmias and Impaired Aerobic Capacity in Tetralogy of Fallot and Other Congenital Heart Diseases

Mayo Clinic

Start Date

11/1/2021

Completion Date

10/1/2026

Summary

This study is being done to determine the mechanism(s) contributing to the onset of symptoms (i.e. shortness of breath and/or palpitations) as well as changes in heart structure in patients with congenital heart disease (CHD)

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: * Moderate (or greater) PR based on quantitative Doppler echocardiography. * Repaired TOF * Congenital Heart Disease diagnosis including but not limited to Ebstein's anomaly, coarctation of the aorta (COA), Fontan palliation, transposition of the great arteries, congenitally corrected transposition of the great arteries. Exclusion Criteria: * Pregnant Women * Unable to undergo CMRI

Interventions

DIAGNOSTIC_TEST

Remote Heart Rhythm Monitoring

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Tetralogy of FallotCongenital Heart Disease

Locations

Mayo Clinic in Rochester

Rochester, Minnesota 55905

United States

Run studies, or work at a research site?

Corterve helps sites and sponsors reach patients who are looking for trials. It does not determine eligibility and does not promise an enrolment outcome.

For sponsors, CROs and sites

What Corterve sells to organisations, and the anti-kickback constraints it works within.

Services and published prices

Lay summaries for EU CTR Annex V, pre-screen filtration, recruitment-creative regulatory operations, feasibility reporting.

For research sites

One published licence rate, the same for every site, and the fees a site is never charged.